Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 1_Sex differences in the reactivity of gastric myoelectrical activity and heart rate variability as putative psychophysiological markers in human pain research.docx by Rossitza Draganova (9154951)

“…</p>Results<p>Acute pain induced significant instability in EGG slow-wave frequency and amplitude, increased tachygastria, and decreased normogastric spectral power, without evidence of sex differences. …”

Neurochemical identity of dFB^23E10Ո^84C10 neurons. by Joseph D. Jones (13883524)

“…A Kruskal–Wallis ANOVA followed by Dunn’s multiple comparisons revealed that acutely silencing VGlut-AD; 84C10-DBD and 84C10-AD; ChAT-DBD neurons significantly decreases sleep. ****<i>P</i> < 0.0001. …”

Table 1_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.xlsx by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 3_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 4_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 1_Effects of drospirenone and ethinylestradiol tablets (II) combined with metformin on the composition of gut microbiota in polycystic ovary syndrome with insulin resist... by Yanglu Liu (22417861)

“…After treatment, CHO levels decreased in PCOS-NIR group (P < 0.05); FINS, LDL-C and HOMA-IR decreased and HDL-C levels increased in PCOS-IR group (P < 0.05). 2. …”

Data Sheet 5_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 6_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”